mercredi 18 mai 2016

Immune drug for deadly skin cancer shows long-term survival

CHICAGO (AP) - A new kind of drug for the deadliest form of skin cancer helped some patients survive for at least three years, a study shows. It's a remarkable advance for patients who until recently faced dismal chances of living for more than a few months.

About 40 percent of melanoma patients in the study were still alive three years later.

Immune drug for deadly skin cancer shows long-term survival

Aucun commentaire:

Enregistrer un commentaire